Evidence map›Paper›PMID 42088619›Full record

ArticleMolecular therapy. Oncology2026

NeuroD1 gene therapy inhibits glioma growth and extends life span through

Yuchen Chen, Zuoyu Jiang, Sen Jin, Meng Liu, Ming Chen, Tsang-Chih Kuo, Kai Zhou, Liting Pu, Ming Chen, Shiyuan Chen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molecular therapy. Oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yuchen ChenNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Zuoyu JiangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.
Sen JinNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Meng LiuNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Ming ChenNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Tsang-Chih KuoNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Kai ZhouNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Liting PuNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Ming ChenNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Shiyuan ChenNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Xuetao LiDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.
Adalia S ChenNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Jingmu XieGuangdong-Hong Kong-Macau Institute of CNS Regeneration (GHMICR), Jinan University, Guangzhou 510632, China.
Huitao ZhangGuangdong-Hong Kong-Macau Institute of CNS Regeneration (GHMICR), Jinan University, Guangzhou 510632, China.
Qingsong WangGuangdong-Hong Kong-Macau Institute of CNS Regeneration (GHMICR), Jinan University, Guangzhou 510632, China.
Jie XuNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Jian ShengNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.
Yulun HuangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China.
Gong ChenNeuExcell Therapeutics, 218 Xinghu Street, Building B1, Floor 9, Suzhou, Jiangsu 215000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma(GBM), a highly aggressive primary brain tumor characterized by rapid progression, frequent recurrence, and limited clinical options, remains one of the most lethal central nervous system malignancies. Here, we report a gene therapy strategy to treat glioma utilizing NeuroD1, a neurogenic transcription factor with demonstrated capacity to reprogram both glial cells and GBM cells into neuronal lineages. We developed a self-complementary adeno-associated virus (scAAV) vector, scAAV6-NeuroD1, and evaluated its therapeutic potential across

Indexed as

AAVGBMgene therapyglioblastomaNeuroD1survival extensiontumor reprogramming

Identifiers

PMID42088619
PMCPMC13136644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.